Henan Lingrui Pharmaceutical Co (SHSE:600285) Risk Assessment

View and export this data going back to 2000. Start your Free Trial

What is Henan Lingrui Pharmaceutical Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Henan Lingrui Pharmaceutical Co is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Henan Lingrui Pharmaceutical Co's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Henan Lingrui Pharmaceutical Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Henan Lingrui Pharmaceutical Co's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Henan Lingrui Pharmaceutical Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Henan Lingrui Pharmaceutical Co's Risk Assessment falls into.

Henan Lingrui Pharmaceutical Co (SHSE:600285) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Henan Lingrui Pharmaceutical Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Henan Lingrui Pharmaceutical Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Henan Lingrui Pharmaceutical Co (SHSE:600285) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Henan Lingrui Pharmaceutical Co Ltd (SHSE:600285) » Definitions » Risk Assessment

Traded in Other Exchanges

N/A

Address

No. 59 Jiefang Chengguan Road, Xinxian, Xinyang, Henan, CHN, 465550

Website

http://www.lingrui.com

Henan Lingrui Pharmaceutical Co Ltd is a Chinese company engaged in the development, production, and distribution of pharmaceuticals. The Company's products include tablets, capsules, injections and other medicines.

Executives

Wu Xi Zhen	Director
Li Jin	Supervisors
Ye Qiang	senior management
Chen Yan	Directors, senior managers
Wu Hui Bin	senior management
Yu Peng	Director
Zhao Zhi Jun	Director
Li Lei	senior management
Feng Guo Xin	Directors, senior managers
Pan Zi Run	Director
Xiong Wei Zheng	Director
Tang Wei	Supervisors
Cheng Jian Jun	Director
Zhang Jun Bing	Director
Xia Hui	senior management

Henan Lingrui Pharmaceutical Co (SHSE:600285) Headlines

No Headlines